Drug Topics
APRIL 7, 2025
Researchers explored various types of self-expression among pharmacists and how they were associated with experience in community pharmacy-led deprescribing.
The FDA Law Blog
APRIL 8, 2025
By Kurt R. Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As the dust begins to settle and we all assess what this means for the future of FDA and the public health, generally, this blogger wanted to call out one particular division in the Office of Generic Drugs (OGD), funded by user fees under the Generic Drug User Fee Amendments (GDUFA), that was eradicated and what t
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 9, 2025
A national public health organization is calling for Health Secretary Robert F. Kennedy Jr. to resign the federal post he assumed just weeks ago, citing “implicit and explicit bias and complete disregard for science.” Georges Benjamin, executive director of the American Public Health Association, said in a statement on Wednesday that concerns raised during Kennedy’s confirmation hearing last month have been realized, followed by massive reductions in staff at key health agen
PhRMA
APRIL 7, 2025
For more than four decades since the passage of the Hatch-Waxman Act, the U.S. generic drug market has provided patients with low-cost alternatives to brand-name medicines, saving the health care system billions while preserving incentives for biopharmaceutical innovation. Today, low-cost generics account for nine out of every 10 prescriptions dispensed in the United States and come with an average copay of about six dollars.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 11, 2025
The designation addresses the unmet need for prevention of H5N1, which remains a global health risk, and a phase 1 trial of the vaccine was initiated in November 2024.
PharmaVoice
APRIL 11, 2025
The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
European Pharmaceutical Review
APRIL 11, 2025
The National Institute For Health and Care Excellence ( NICE )s has recommended a new combination treatment for advanced breast cancer patients. AstraZenecas Truqap (capivasertib) in combination with fulvestrant is indicated as a treatment option for around 1,100 UK adults with hormone receptor (HR)-positive HER2-negative breast cancer with certain genetic mutations.
Drug Topics
APRIL 10, 2025
A conversation with Douglas Hoey, CEO of the National Community Pharmacists Association, at the American Associated Pharmacies 2025 Annual Conference.
PharmaVoice
APRIL 7, 2025
So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?
STAT
APRIL 8, 2025
Last week’s layoffs across the Department of Health and Human Services left a significant casualty in the vast ecosystem of government-backed science: an entire division focused on researching pain. The reduction in force enacted last week by Health Secretary Robert F. Kennedy Jr. eliminated all but one full-time position, out of roughly a dozen, within the National Institutes of Health Office of Pain Policy and Planning, a unit devoted to coordinating pain-related research across t
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmafile
APRIL 10, 2025
Dosium Touchdose has gone live at West Middlesex University Hospital, UK, a clinical decision support technology proven to significantly reduce prescribing errors. This follows go-live at both Chelsea and Westminster Hospital last month, and St Marys Hospital last summer, marking the final stage of rollout across the entire West London Childrens Healthcare (WLCH) partnership.
Drug Topics
APRIL 8, 2025
In a comprehensive review, researchers aimed to explore seasonality, environmental factors, and the genetic and epigenetic mechanisms of patients living with psoriasis vulgaris.
The Checkup by Singlecare
APRIL 9, 2025
People with Type 2 Diabetes have many treatment options these days, though not all are covered by insurance. Ozempic is a prescription weekly injection manufactured by Novo Nordisk. It is often covered by insurance when prescribed for diabetes (not weight loss ). However, not all insurance plans cover Ozempic and when it is covered, the coverage amount may vary by provider and plan.
STAT
APRIL 11, 2025
In an unexpected move, the U.S. Food and Drug Administration announced plans this week to reduce — and possibly replace — animal testing with other methods for developing certain medicines in a bid to lower R&D costs and, eventually, the prices for prescription drugs. The agency will encourage researchers to use computer modeling and artificial intelligence to predict how a drug will perform, as well as organs-on-a-chip, which are miniaturized devices that mimic organs and tiss
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmaVoice
APRIL 7, 2025
The FDA is much more flexible in approving first-in-class drugs compared to European regulators.
Drug Topics
APRIL 8, 2025
In a review of skin inflammations link to food allergen sensitivity, researchers explored how patients with atopic dermatitis may be more susceptible to the development of food allergies.
The Checkup by Singlecare
APRIL 10, 2025
Strattera (atomoxetine) is a brand name, non-stimulant drug approved by the U.S. Food and Drug Administration (FDA) to treat attention deficit hyperactivity disorder (ADHD). Its also prescribed off-label for other medical conditions, such as treating a specific type of low blood pressure called neurogenic orthostatic hypotension and reducing symptoms of major depressive disorder in people who also have ADHD.
STAT
APRIL 10, 2025
Mark Ratain’s First Opinion piece of Feb. 4, 2025 , implies that the oncologists in NCI’s Investigational Drug Branch (IDB) colluded with the drug company Exilixis to sponsor two Phase 3 studies of its drug cabozantanib. He claims these studies showed minimal benefit, yet the results were used to inflate the value of Exilixis stock. Ratain concludes by recommending that IDB be abolished.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmafile
APRIL 10, 2025
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over a period of at least 18 months. If approved by regulators, HMTM could be the first oral treatment for the disease that targets the tau protein. Conventionally, targeted therapies for Alzheimers focused on amyloid protein […] The post Research finds tablet effective in slowing progression of Alzheimers disease over 18 months appeared f
Drug Topics
APRIL 8, 2025
Conflicting study findings show various associations between asthma and COVID-19; further data are needed.
The Checkup by Singlecare
APRIL 9, 2025
Atorvastatin , a medication in the statin drug class , is prescribed to treat high cholesterol. Available in both tablet and liquid form, atorvastatin blocks the enzyme needed to make low-density lipoprotein (LDL) cholesterol (aka bad cholesterol) in the liver. Since high cholesterol can cause heart attacks and strokes, and this risk increases as people age, older adults may be more likely to need lipid-lowering agents like atorvastatin.
STAT
APRIL 9, 2025
Amid the hard-to-follow cutbacks at the U.S. Food and Drug Administration, a little-known but important office was eliminated — and the implications will be felt not only by drugmakers, but consumers. The Division of Policy Development in the Office of Generic Drug Policy, which was created more than a decade ago, was responsible for a host of activities that were central to ensuring generic drugs were approved properly for the American market.
PhRMA
APRIL 10, 2025
These days, the same big health care conglomerate could own your PBM, insurer, pharmacy and even your doctor’s office. Middlemen now control what medicines you can get, what you pay at the pharmacy counter, what pharmacy you can you use and what hoops you must jump through to get the medicine your doctor prescribed.
Drug Topics
APRIL 11, 2025
Collaborative practice agreements enable pharmacists to leverage their expertise beyond traditional dispensing, but barriers continue to limit their implementation.
Hospital Pharmacy Europe
APRIL 10, 2025
Non-adherence can negatively impact medication treatment strategies, particularly among oncology patients, driving up treatment costs while potentially worsening clinical outcomes. Although oral oncolytics offer convenience, they arguably require greater patient engagement in remembering to take their treatment, often resulting in lower adherence compared to infused therapies.
STAT
APRIL 11, 2025
WASHINGTON — An Alabama woman who lived with a pig kidney for a record 130 days had the organ removed after her body began rejecting it and is back on dialysis, doctors announced Friday — a disappointment in the ongoing quest for animal-to-human transplants. Towana Looney is recovering well from the April 4 removal surgery at NYU Langone Health and has returned home to Gadsden, Alabama.
Pharmacy Times
APRIL 7, 2025
Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.
Drug Topics
APRIL 9, 2025
The drug shows a decrease in proteinuria and is well tolerated and safe, including for Black patients with chronic kidney disease.
Hospital Pharmacy Europe
APRIL 10, 2025
A tool to streamline hospital outpatient clinics for geriatric oncology patients has been developed by a clinical pharmacist and clinical nurse specialist at the Royal Marsden NHS Foundation Trust. The eArly identifiCation advanCed gEriatric aSsesSment (ACCESS) tool facilitates integrated care by remotely assessing medications, nutrition, social support, mood, and functional status, enhancing clinical efficiency and patient outcomes.
STAT
APRIL 10, 2025
A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences should issue compulsory licenses if the company fails to modify an existing licensing program with half a dozen generic makers. In an essay in Clinical Infectious Diseases , they complained Gilead pursued voluntary licenses that are too restrictive, which will delay or deny access to its drug.
PharmaVoice
APRIL 9, 2025
“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.
Drug Topics
APRIL 10, 2025
Using a cost-utility analysis, researchers addressed the cost-effectiveness of pneumococcal vaccine strategies for adults over the age of 64.
Hospital Pharmacy Europe
APRIL 7, 2025
Theranostics integrates diagnostic and therapeutic radiopharmaceuticals targeting the same molecular structures delivering a one-two punch for personalised cancer care. In his latest commentary, Professor Alain Astier discusses how the radionuclide 177Lu and 177Lu-based radioligands have gained traction in treating various conditions, including neuroendocrine tumours and metastatic prostate cancer.
Expert insights. Personalized for you.
499 
Let's personalize your content